Shingo Kobari
Overview
Explore the profile of Shingo Kobari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Temizoz B, Hioki K, Kobari S, Jounai N, Kusakabe T, Lee M, et al.
Int Immunol
. 2022 Apr;
34(7):353-364.
PMID: 35419609
Agonists for TLR9 and stimulator of IFN genes (STING) offer therapeutic applications as both anti-tumor agents and vaccine adjuvants, though their clinical applications are limited; the clinically available TLR9 agonist...
2.
Kobari S, Kusakabe T, Momota M, Shibahara T, Hayashi T, Ozasa K, et al.
Front Immunol
. 2020 Mar;
11:360.
PMID: 32210964
Vaccine adjuvants are traditionally used to augment and modulate the immunogenicity of vaccines, although in many cases it is unclear which specific molecules contribute to their stimulatory activity. We previously...
3.
Ozasa K, Temizoz B, Kusakabe T, Kobari S, Momota M, Coban C, et al.
Front Immunol
. 2019 Oct;
10:2212.
PMID: 31616416
Extracellular host-derived DNA, as one of damage associated molecular patterns (DAMPs), is associated with allergic type 2 immune responses. Immune recognition of such DNA generates the second messenger cyclic GMP-AMP...
4.
Nagatake T, Hirata S, Koga T, Kuroda E, Kobari S, Suzuki H, et al.
Mucosal Immunol
. 2019 May;
12(5):1082-1091.
PMID: 31142830
Leukotriene B receptor 1 (BLT1) triggers the migration of granulocytes and activated T cells; however, its role in B-cell function remains unclear. Here we report that BLT1 is required to...
5.
Hayashi T, Momota M, Kuroda E, Kusakabe T, Kobari S, Makisaka K, et al.
Front Immunol
. 2018 Dec;
9:2619.
PMID: 30515151
Recently, it was reported that 2-hydroxypropyl-β-cyclodextrin (HP-β-CyD), a common pharmaceutical additive, can act as a vaccine adjuvant to enhance protective type-2 immunogenicity to co-administered seasonal influenza split vaccine by inducing...
6.
Kuroda E, Ozasa K, Temizoz B, Ohata K, Koo C, Kanuma T, et al.
Immunity
. 2016 Dec;
45(6):1299-1310.
PMID: 28002730
Particulate pollution is thought to function as an adjuvant that can induce allergic responses. However, the exact cell types and immunological factors that initiate the lung-specific immune responses are unclear....
7.
Hayashi M, Aoshi T, Ozasa K, Kusakabe T, Momota M, Haseda Y, et al.
Sci Rep
. 2016 Jul;
6:29165.
PMID: 27374884
Nasal vaccination has the potential to elicit systemic and mucosal immunity against pathogens. However, split and subunit vaccines lack potency at stimulating mucosal immunity, and an adjuvant is indispensable for...
8.
Kusakabe T, Ozasa K, Kobari S, Momota M, Kishishita N, Kobiyama K, et al.
Vaccine
. 2016 May;
34(27):3191-3198.
PMID: 27160037
Intranasal vaccination with inactivated influenza viral antigens is an attractive and valid alternative to currently available influenza (flu) vaccines; many of which seem to need efficient and safe adjuvant, however....